logo-loader

Full interview: Arcadia Biosciences records some big wins in the 3rd Quarter

Published: 15:26 07 Nov 2019 EST

Arcadia Biosciences (NASDAQ: RKDA) CEP Matt Plavan joined Proactive’s Steve Darling to discuss the company’s third-quarter results. Plavan also discussed some of the company highlights during that quarter including the latest on their research facilities.

Plavan also discussed their hemp operation and the expansion they had in three states.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 13 minutes ago